In conditions such as B-cell acute lymphoblastic leukemia (B-ALL), annexin A2–mediated plasmin activation promotes ECM degradation and disease progression, effects that can be mitigated by plasmin inhibition [42,43,44]. The gene discussed is PLG; the disease is precursor B-cell acute lymphoblastic leukemia.